{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:01:57Z","timestamp":1790074917556,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12917-018-1597-7","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T11:00:32Z","timestamp":1535972432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Retrospective evaluation of toceranib phosphate (Palladia\u00ae) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014\u20132017)"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4350-0614","authenticated-orcid":false,"given":"Margaret L.","family":"Musser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Taikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad M.","family":"Johannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"key":"1597_CR1","doi-asserted-by":"crossref","unstructured":"Galac S, Korpershoek E. Pheochromocytomas and paragangliomas in humans and dogs. Vet comp Oncol, Epub. 2017;","DOI":"10.1111\/vco.12291"},{"key":"1597_CR2","first-page":"512","volume-title":"Withrow and MacEwan\u2019s small animal clinical oncology","author":"KF Lunn","year":"2013","unstructured":"Lunn KF, Page RL. Tumors of the endocrine system. In: Withrow SJ, Vail DM, Page RL, editors. Withrow and MacEwan\u2019s small animal clinical oncology. 5th ed. St. Louis: Elsevier; 2013. p. 512\u20133.","edition":"5"},{"key":"1597_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/jvim.12009","volume":"27","author":"R Gostelow","year":"2013","unstructured":"Gostelow R, Bridger N, Syme HM. Plasma-free metanephrine and free normetanephrine measurement for the diagnosis of pheochromocytoma in dogs. J Vet Intern Med. 2013;27:83\u201390.","journal-title":"J Vet Intern Med"},{"key":"1597_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2460\/javma.2003.223.654","volume":"223","author":"AE Kyles","year":"2003","unstructured":"Kyles AE, Feldman EC, De Cock HEV, et al. Surgical management of adrenal gland tumors with and without associated tumor thrombi in dogs: 40 cases (1994-2001). J Am Vet Med Assoc. 2003;223:654\u201362.","journal-title":"J Am Vet Med Assoc"},{"key":"1597_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1939-1676.2008.0182.x","volume":"22","author":"MA Herrera","year":"2008","unstructured":"Herrera MA, Mehl ML, Kass PH, et al. Predictive factors and the effect of phenoxybenzamine on outcome in dogs undergoing adrenalectomy for pheochromocytoma. J Vet Intern Med. 2008;22:1333\u20139.","journal-title":"J Vet Intern Med"},{"key":"1597_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2460\/javma.239.2.216","volume":"239","author":"F Massari","year":"2011","unstructured":"Massari F, Nicoli S, Romanelli G, et al. Adrenalectomy in dogs with adrenal gland tumors: 52 cases (2002-2008). J Am Vet Med Assoc. 2011;239:216\u201321.","journal-title":"J Am Vet Med Assoc"},{"key":"1597_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2460\/javma.232.1.77","volume":"232","author":"P Schwartz","year":"2008","unstructured":"Schwartz P, Kovak JR, Koprowski A, et al. Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999-2005). J Am Vet Med Assoc. 2008;232:77\u201384.","journal-title":"J Am Vet Med Assoc"},{"key":"1597_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1939-1676.1997.tb00464.x","volume":"11","author":"PY Barthez","year":"1997","unstructured":"Barthez PY, Marks SL, Woo J, et al. Pheochromocytoma in dogs: 61 cases (1984-1995). J Vet Intern Med. 1997;11:272\u20138.","journal-title":"J Vet Intern Med"},{"key":"1597_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1532-950X.1994.tb00472.x","volume":"23","author":"SD Gilson","year":"1994","unstructured":"Gilson SD, Withrow SJ, Orton EC. Surgical treatment of pheochromocytoma: technique, complications, and results in six dogs. Vet Surg. 1994;23:195\u2013200.","journal-title":"Vet Surg"},{"key":"1597_CR10","first-page":"802","volume":"12","author":"CM Beard","year":"1983","unstructured":"Beard CM, Sheps SG, Kurland LT, et al. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 though 1979. Mayo Clin Proc. 1983;12:802\u20134.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1597_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.0954-6820.1986.tb02755.x","volume":"220","author":"G Stenstr\u00f6m","year":"1986","unstructured":"Stenstr\u00f6m G, Sv\u00e4rdsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the national Cancer registry data. Acta Med Scand. 1986;220(3):225\u201332.","journal-title":"Acta Med Scand"},{"issue":"5","key":"1597_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/01.HYP.29.5.1133","volume":"29","author":"PF Plouin","year":"1997","unstructured":"Plouin PF, Chatellier G, Fofol I, et al. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997;29(5):1133\u20139.","journal-title":"Hypertension"},{"issue":"3","key":"1597_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF01658516","volume":"14","author":"JA van Heerden","year":"1990","unstructured":"van Heerden JA, Roland CF, Carney JA, et al. Long-term evaluation following resection of apparently benign pheochromocytoma(s)\/paraganglioma(s). World J Surg. 1990;14(3):325\u20139.","journal-title":"World J Surg"},{"issue":"4","key":"1597_CR14","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1210\/jc.2004-1398","volume":"90","author":"L Amar","year":"2005","unstructured":"Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90(4):2110\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1597_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","volume":"109","author":"SD Averbuch","year":"1988","unstructured":"Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109(4):267\u201373.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1597_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1210\/jc.2008-1972","volume":"94","author":"C Jimenez","year":"2009","unstructured":"Jimenez C, Cabanillas ME, Santarpia L, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009;94(2):386\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1597_CR17","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Chougnet CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97(11):4040\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1597_CR18","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884\u201396.","journal-title":"J Clin Oncol"},{"key":"1597_CR19","doi-asserted-by":"publisher","first-page":"E615","DOI":"10.1152\/ajpendo.00035.2011","volume":"302","author":"Y Saito","year":"2012","unstructured":"Saito Y, Tanaka Y, Aita Y, et al. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2\/Akt\/mTOR\/S6K1 pathways through modulation of Bcl-2 and BAD. Am J Physiol Endocrinol Metab. 2012;302:E615\u201325.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"1597_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/jc.2008-1836","volume":"94","author":"AM Joshua","year":"2009","unstructured":"Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma. J Clin Endocrinol Metab. 2009;94(1):5\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1597_CR21","first-page":"2755","volume":"9","author":"CA London","year":"2003","unstructured":"London CA, Hannah AL, Zadovoskya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003;9:2755\u201368.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1597_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1053\/j.tcam.2009.02.002","volume":"24","author":"CA London","year":"2009","unstructured":"London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med. 2009;24(3):106\u201312.","journal-title":"Top Companion Anim Med"},{"key":"1597_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1939-1676.2007.tb02980.x","volume":"21","author":"PH Kook","year":"2007","unstructured":"Kook PH, Boretti FS. Hersberger, et al. urinary catecholamine and metanephrine to creatinine ratios in healthy dogs at home and in a hospital environment and in 2 dogs with pheochromocytoma. J Vet Intern Med. 2007;21:388\u201393.","journal-title":"J Vet Intern Med"},{"issue":"6","key":"1597_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/vr.b4760","volume":"166","author":"PH Kook","year":"2010","unstructured":"Kook PH, Grest P, Quante S, et al. Urinary catecholamine and metadrenaline to creatinine ratios in dogs with a pheochromocytoma. Vet Rec. 2010;166(6):169\u201374.","journal-title":"Vet Rec"},{"issue":"5","key":"1597_CR25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/j.1939-1676.2010.0578.x","volume":"24","author":"S Quante","year":"2010","unstructured":"Quante S, Boretti FS, Kook PH, et al. Urinary catecholamine and metanephrine to creatinine ratios in dogs with hyperadrenocorticism or pheochromocytoma, and in healthy dogs. J Vet Intern Med. 2010;24(5):1093\u20137.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"1597_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/vcp.12093","volume":"42","author":"BA Green","year":"2013","unstructured":"Green BA, Frank EL. Comparison of plasma free metanephrines between healthy dogs and 3 dogs with pheochromocytoma. Vet Clin Pathol. 2013;42(4):499\u2013503.","journal-title":"Vet Clin Pathol"},{"issue":"2","key":"1597_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/jvim.12569","volume":"29","author":"E Salesov","year":"2015","unstructured":"Salesov E, Boretti FS, Sieber-Ruckstuhl NS, et al. Urinary and plasma catecholamines and metanephrines in dogs with pheochromocytoma, hypercortisolism, nonadrenal disease and in healthy dogs. J Vet Intern Med. 2015;29(2):597\u2013602.","journal-title":"J Vet Intern Med"},{"issue":"3","key":"1597_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","volume":"13","author":"SM Nguyen","year":"2015","unstructured":"Nguyen SM, Thamm DH, Vail DM, et al. Response evaluation criteria for solid tumors in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2015;13(3):176\u201383.","journal-title":"Vet Comp Oncol"},{"key":"1597_CR29","doi-asserted-by":"crossref","unstructured":"Veterinary cooperative oncology group \u2013 common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417\u201346.","DOI":"10.1111\/vco.283"},{"issue":"3","key":"1597_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1476-5829.2011.00275.x","volume":"10","author":"C London","year":"2012","unstructured":"London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (palladia\u00ae) in solid tumours. Vet Comp Oncol. 2012;10(3):194\u2013205.","journal-title":"Vet Comp Oncol"},{"key":"1597_CR31","first-page":"289","volume":"7","author":"JE Moulton","year":"1971","unstructured":"Moulton JE, Taylor DON, Doran CR, et al. Canine mammary tumors. Vet Path. 1971;7:289\u2013320.","journal-title":"Vet Path"},{"issue":"4","key":"1597_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jvim.13951","volume":"30","author":"SS Tjostheim","year":"2016","unstructured":"Tjostheim SS, Stepien RL, Markovic LE, et al. Effects of toceranib phosphate in systolic blood pressure and proteinuria in dogs. J Vet Intern Med. 2016;30(4):951\u20137.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"1597_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc3648","volume":"14","author":"PLM Dahia","year":"2014","unstructured":"Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108\u201319.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1597_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jcpa.2014.03.007","volume":"151","author":"DE Holt","year":"2014","unstructured":"Holt DE, Henthorn P, Howell VM, et al. Succinate dehydrogenase subunit D and succinate dehydrogenase subunit B mutation analysis in canine phaeochromocytoma and paraganglioma. J Comp Pathol. 2014;151(1):25\u201334.","journal-title":"J Comp Pathol"},{"issue":"3","key":"1597_CR35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1939-1676.2009.0310.x","volume":"23","author":"BM Pressler","year":"2009","unstructured":"Pressler BM, Williams LE, Ramos-Vara JA, et al. Sequencing of the von Hippel-Lindau gene in canine renal carcinoma. J Vet Intern Med. 2009;23(3):592\u20137.","journal-title":"J Vet Intern Med"},{"issue":"6","key":"1597_CR36","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.5326\/JAAHA-MS-5605","volume":"47","author":"DA Bommarito","year":"2011","unstructured":"Bommarito DA, Lattimer JC, Selting KA, et al. Treatment of a malignant pheochromocytoma in a dog using 131I metaiodobenzylguanidine. J Am Anim Hosp Assoc. 2011;47(6):e188\u201394.","journal-title":"J Am Anim Hosp Assoc"},{"key":"1597_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1746-6148-9-190","volume":"9","author":"LF Bernabe","year":"2013","unstructured":"Bernabe LF, Portela R, Nguyen S, et al. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res. 2013;9:190.","journal-title":"BMC Vet Res"},{"issue":"1","key":"1597_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.critrevonc.2014.01.002","volume":"91","author":"SC Sodergren","year":"2014","unstructured":"Sodergren SC, White A, Efficace F, et al. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumors of behalf of the EORTC quality of life group. Crit Rec Oncol Hematol. 2014;91(1):35\u201346.","journal-title":"Crit Rec Oncol Hematol"},{"issue":"1","key":"1597_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CAD.0b013e3283403806","volume":"22","author":"G Aparicio-Gallego","year":"2011","unstructured":"Aparicio-Gallego G, Afonso-Afonso FJ, Le\u00f3n-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitinib. Anti-Cancer Drugs. 2011;22(1):1\u20138.","journal-title":"Anti-Cancer Drugs"},{"issue":"12","key":"1597_CR40","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1093\/annonc\/mds179","volume":"23","author":"S George","year":"2012","unstructured":"George S, Reichardt P, Lechner T, et al. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012;23(12):3180\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"1597_CR41","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1210\/jc.2006-1544","volume":"92","author":"T Scholz","year":"2007","unstructured":"Scholz T, Eisenhofer G, Pacak K, et al. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;92(4):1217\u201325.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-018-1597-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-018-1597-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-018-1597-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T19:07:16Z","timestamp":1567451236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-018-1597-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1186\/s12917-018-1597-7","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,3]]},"assertion":[{"value":"12 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable \u2013 retrospective records review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CMJ is a former employee of Pfizer Animal Health and has served as a member of the Zoetis Inc. (formerly Pfizer Animal Health) Oncology Advisory Board and occasionally received honoraria for these activities. PJB is a Palladia Advisory Board member and has ongoing studies sponsored by Zoetis. The remaining authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"272"}}